BIOMAT Database Logo BIOMAT Database Logo

Skin involvement in ALK-negative systemic anaplastic large-cell lymphoma. 2012

Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077548 Anaplastic Lymphoma Kinase A receptor tyrosine kinase that is essential for development and differentiation of the nervous system in response to secreted growth factors. It phosphorylates the first tyrosine of the Y-x-x-x-Y-Y motif of targets that include PROTO-ONCOGENE PROTEINS C-CBL; INSULIN RECEPTOR SUBSTRATE-1; and MITOGEN-ACTIVATED PROTEIN KINASES, leading to activation of the MAPK signaling pathway and cell proliferation. A chromosomal aberration involving the ALK gene results in its constitutive expression in some cases of NON-HODGKIN LYMPHOMA. ALK Kinase,ALK Tyrosine Kinase Receptor,Anaplastic Lymphoma Receptor Tyrosine Kinase,CD246 Antigen,NPM-ALK,Nucleophosmin-Anaplastic Lymphoma Kinase,Nucleophosmin Anaplastic Lymphoma Kinase
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017728 Lymphoma, Large-Cell, Anaplastic A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS. Anaplastic Large-Cell Lymphoma,CD30-Positive Anaplastic Large-Cell Lymphoma,Lymphoma, Large-Cell, Ki-1,CD30+ Anaplastic Large-Cell Lymphoma,Ki-1 Lymphoma,Systemic Anaplastic Large-Cell Lymphoma,Anaplastic Large Cell Lymphoma,Anaplastic Large-Cell Lymphomas,CD30 Positive Anaplastic Large Cell Lymphoma,CD30+ Anaplastic Large Cell Lymphoma,Ki 1 Lymphoma,Ki-1 Lymphomas,Large-Cell Lymphoma, Anaplastic,Large-Cell Lymphomas, Anaplastic,Lymphoma, Anaplastic Large-Cell,Lymphoma, Ki-1,Lymphomas, Anaplastic Large-Cell,Lymphomas, Ki-1,Systemic Anaplastic Large Cell Lymphoma
D020794 Receptor Protein-Tyrosine Kinases A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity. PTK Receptor,Receptors, Protein-Tyrosine Kinase,Tyrosine Kinase Linked Receptor,Tyrosine Kinase Linked Receptors,Tyrosine Kinase Receptor,Tyrosine Kinase Receptors,PTK Receptors,Protein-Tyrosine Kinase Receptor,Receptor Protein-Tyrosine Kinase,Kinase Receptor, Tyrosine,Kinase, Receptor Protein-Tyrosine,Kinases, Receptor Protein-Tyrosine,Protein-Tyrosine Kinase Receptors,Protein-Tyrosine Kinase, Receptor,Protein-Tyrosine Kinases, Receptor,Receptor Protein Tyrosine Kinase,Receptor Protein Tyrosine Kinases,Receptor, PTK,Receptor, Protein-Tyrosine Kinase,Receptor, Tyrosine Kinase,Receptors, PTK,Receptors, Protein Tyrosine Kinase

Related Publications

Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Anaplastic Lymphoma Kinase (ALK)-negative systemic anaplastic large cell lymphoma presenting as zosteriform skin nodules.
November 2023, Indian journal of dermatology, venereology and leprology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
ALK-negative systemic intravascular anaplastic large cell lymphoma presenting in the skin.
February 2011, Journal of cutaneous pathology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
ALK-negative anaplastic large-cell lymphoma.
January 2016, Blood,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Anaplastic large cell lymphoma, ALK-negative.
February 2013, Critical reviews in oncology/hematology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.
November 2017, American journal of hematology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
The expressions of MUM-1 and Bcl-6 in ALK-negative systemic anaplastic large cell lymphoma with skin involvement and primary cutaneous anaplastic large cell lymphoma.
January 2020, International journal of clinical and experimental pathology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
[Granulomatous slack skin associated with ALK-negative anaplastic large cell lymphoma].
December 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma.
January 2020, Academic pathology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Primary pancreatic ALK negative anaplastic large cell lymphoma.
January 2015, Pathology,
Daichi Hoshina, and Ken Arita, and Osamu Mizuno, and Katsuya Fujimoto, and Mitsufumi Nishio, and Takeshi Kondo, and Riichiro Abe, and Hiroshi Shimizu
Pathobiology of ALK-negative anaplastic large cell lymphoma.
June 2011, Pediatric reports,
Copied contents to your clipboard!